Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging study reveals how glaucoma drug works inside the eye

NCT ID NCT07588152

Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses special cameras to take detailed pictures of the eye's drainage system in people with glaucoma or high eye pressure. Half of the 50 participants will use Rhopressa eye drops daily for two weeks, while the other half will use artificial tears. The goal is to see if Rhopressa changes the structure of the drainage tissue, which may explain how it lowers eye pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Netarsudil ophthalmic solution (Rhopressa)
What this could lead to
If successful, this study could help explain how Rhopressa lowers eye pressure, potentially leading to better treatments for glaucoma.
What could go wrong
This is a small, early-phase imaging study, not a large trial testing long-term outcomes. The results may not directly translate to better patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of ocular hypertension or open-angle glaucoma * Eye examination within the past year * For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma * Best-corrected visual acuity of 20/100 or better * Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT) * Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable) Exclusion Criteria: * Known intolerance to netarsudil ophthalmic solution * Corneal scarring or active corneal disease that would interfere with imaging * Inability to tolerate gonioscopy procedures * Females of childbearing potential who are not using effective contraception or are not sterile * Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma Ocular hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Indiana Universtiy School of Optometry

    RECRUITING

    Bloomington, Indiana, 47405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.